X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GLENMARK PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GLENMARK PHARMA DIVIS LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 39.3 25.1 156.7% View Chart
P/BV x 6.4 3.9 162.2% View Chart
Dividend Yield % 0.7 0.3 229.1%  

Financials

 DIVIS LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
GLENMARK PHARMA
Mar-17
DIVIS LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,142993 115.0%   
Low Rs533729 73.1%   
Sales per share (Unadj.) Rs146.6325.5 45.0%  
Earnings per share (Unadj.) Rs33.039.3 84.1%  
Cash flow per share (Unadj.) Rs38.448.7 78.9%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.20.2 514.2%  
Book value per share (Unadj.) Rs222.8159.2 140.0%  
Shares outstanding (eoy) m265.47282.17 94.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.72.6 216.0%   
Avg P/E ratio x25.321.9 115.7%  
P/CF ratio (eoy) x21.817.7 123.2%  
Price / Book Value ratio x3.85.4 69.5%  
Dividend payout %30.35.1 594.7%   
Avg Mkt Cap Rs m222,318242,991 91.5%   
No. of employees `00010.813.0 83.0%   
Total wages/salary Rs m4,56116,408 27.8%   
Avg. sales/employee Rs Th3,616.07,083.9 51.0%   
Avg. wages/employee Rs Th423.81,265.4 33.5%   
Avg. net profit/employee Rs Th814.9855.1 95.3%   
INCOME DATA
Net Sales Rs m38,91591,857 42.4%  
Other income Rs m1,134374 303.6%   
Total revenues Rs m40,04992,230 43.4%   
Gross profit Rs m12,61720,367 61.9%  
Depreciation Rs m1,4252,644 53.9%   
Interest Rs m132,373 0.6%   
Profit before tax Rs m12,31315,724 78.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m3,5433,827 92.6%   
Profit after tax Rs m8,77011,088 79.1%  
Gross profit margin %32.422.2 146.2%  
Effective tax rate %28.824.3 118.2%   
Net profit margin %22.512.1 186.7%  
BALANCE SHEET DATA
Current assets Rs m45,35168,746 66.0%   
Current liabilities Rs m6,50727,027 24.1%   
Net working cap to sales %99.845.4 219.8%  
Current ratio x7.02.5 274.0%  
Inventory Days Days12785 149.0%  
Debtors Days Days9596 99.6%  
Net fixed assets Rs m21,16024,132 87.7%   
Share capital Rs m531282 188.1%   
"Free" reserves Rs m58,62544,643 131.3%   
Net worth Rs m59,15644,925 131.7%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m67,832117,639 57.7%  
Interest coverage x926.87.6 12,154.0%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.60.8 73.5%   
Return on assets %12.911.4 113.2%  
Return on equity %14.824.7 60.1%  
Return on capital %20.819.1 108.8%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35956,152 57.6%   
Fx outflow Rs m9,0428,084 111.9%   
Net fx Rs m23,31748,068 48.5%   
CASH FLOW
From Operations Rs m7,7596,574 118.0%  
From Investments Rs m-4,783-7,124 67.1%  
From Financial Activity Rs m-3,1425,432 -57.8%  
Net Cashflow Rs m-1661,992 -8.3%  

Share Holding

Indian Promoters % 52.0 48.3 107.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 6.9 171.0%  
FIIs % 19.0 34.4 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.5 163.8%  
Shareholders   31,796 56,727 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ABBOTT INDIA  NATCO PHARMA  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Flat; Pharma Stocks Gain(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 1%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 26, 2018 10:19 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS